Inactive

Modification P00004 SPE2D2-19-D-0068 to invoke Option 3 period effective March 18, 2022 through March 17, 2023. Modification P00003 SPE2D2-19-D-0068 to invoke Option 2 period effective March 18, 2021 ... Modification P00004 SPE2D2-19-D-0068 to invoke Option 3 period effective March 18, 2022 through March 17, 2023. Modification P00003 SPE2D2-19-D-0068 to invoke Option 2 period effective March 18, 2021 through March 17, 2022. Modification P00002 SPE2D2-19-D-0068 to incorporate FAR 52.204-4 and FAR 52.204-25 into subject contract. Modification P00001 SPE2D2-19-D-0068 to invoke Option 1 period effective March 18, 2020 through March 17, 2021. Alfuzosin HCL